Protagonist Therapeutics, Inc
Protagonist Therapeutics is a biopharmaceutical company with peptide-based investigational new chemical entities in different stages of development, all derived from the Company’s proprietary technology platform. Protagonist’s pipeline includes rusfertide, an investigational, injectable hepcidin mimetic currently in a Phase 2 proof-of-concept clinical trial for polycythemia vera (PV), a Phase 2 study in PV subjects with high hematocrit levels, and a Phase 2 study for hereditary hemochromatosis.